阻塞性睡眠呼吸暂停日间嗜睡诊治专家共识
中华医学会呼吸病学分会睡眠呼吸障碍学组基于国内外最新研究制订本专家共识,针对OSA相关日间嗜睡(EDS)的定义、流行病学、临床表现、诊断评估和治疗形成11条推荐意见,旨在规范诊疗并提高临床认识。
要点
- ESS是评估OSA患者EDS的主观工具,推荐阈值10分,MCID为2-3分。
- CPAP是改善OSA患者EDS的一线治疗(1,A)。
- 常规治疗充分依从后仍有残余EDS者,推荐索利氨酯、 pitolisant或莫达非尼(1,A)。
核心结论
- 共识针对OSA相关EDS形成11条推荐意见,涵盖诊断评估与治疗,旨在规范临床诊疗。
研究设计与样本
- 由中华医学会呼吸病学分会睡眠呼吸障碍学组专家参考国内外最新研究进展制订的专家共识。
主要发现
- ESS推荐临床阈值10分,MCID为2-3分(2,B)。
- MWT和MSLT为排除共病睡眠障碍的客观工具,不应独立用于诊断(2,B)。
- KSS和SSS可作为补充评估工具,不应独立用于诊断(4,C)。
- CPAP推荐为改善OSA患者EDS的一线治疗(1,A)。
- 拒绝、不耐受或不依从CPAP者可从口腔矫治器或手术干预中获益,定制口腔矫治器应优先(2,B)。
关键数值与推荐
- ESS作为主观评估工具可用于诊断、严重程度评估和疗效监测,阈值10分,MCID 2-3分(2,B)。
- CPAP为一线治疗(1,A);口腔矫治器或手术可用于拒绝/不耐受/不依从CPAP者(2,B)。
- 常规治疗充分依从后仍有残余EDS者,推荐索利氨酯、pitolisant或莫达非尼(1,A)。
- 拒绝/不耐受/不依从常规治疗者,推荐索利氨酯或pitolisant个体化治疗(1,A),可考虑莫达非尼(2,B)。
- 因证据不足,目前不推荐哌甲酯或右苯丙胺用于OSA相关EDS(无证据,D)。
临床怎么用
- 使用ESS(阈值10分)评估OSA患者EDS并进行严重程度评估和疗效监测。
- CPAP作为一线治疗;拒绝/不耐受/不依从者可选口腔矫治器或手术。
- 常规治疗充分依从后仍有残余EDS者,考虑索利氨酯、pitolisant或莫达非尼。
- 使用促觉醒药物时定期监测疗效与安全性,警惕药物依赖、成瘾和心血管事件风险(3,B)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Obstructive sleep apnea (OSA) is a common sleep-disordered breathing condition. Excessive daytime sleepiness (EDS) is one of the most common clinical manifestations in patients with OSA. Some OSA patients continue to experience residual EDS despite receiving standard treatment. EDS significantly impairs patients' occupational performance and quality of life, increases the risk of traffic accidents, and is an economic burden for both society and individuals. Currently, there are no specific diagnostic or treatment guidelines for EDS in patients with OSA in China. Therefore, the Sleep Disorder Group of Chinese Thoracic Society has developed this expert consensus based on the latest domestic and international research. The consensus provides a detailed discussion on the definition, epidemiology, clinical manifestations, diagnostic approach, and treatment of EDS in OSA, with the aim of providing standardized recommendations for the diagnosis and treatment of EDS in patients with OSA and improving clinical awareness of this condition. The key recommendations are as follows.Recommendation 1: The Epworth sleepiness scale (ESS) is considered as a subjective tool for assessing EDS in patients with OSA. It can be used for diagnosis, severity assessment, and monitoring of treatment effects. A clinical threshold of 10 points is recommended, with a minimum clinically important difference (MCID) of 2-3 points (2, B).Recommendation 2: The maintenance of wakefulness test (MWT) and the multiple sleep latency test (MSLT) are considered to be objective tools for ruling out comorbid sleep disorders. They should not be used independently for diagnosis (2, B).Recommendation 3: The Karolinska sleepiness scale (KSS) and the Stanford sleepiness scale (SSS) can be used as supplementary assessment tools for EDS, but should not be used independently for diagnosis (4, C).Recommendation 4: CPAP is recommended as the first-line therapy for patients with OSA to improve EDS (1, A).Recommendation 5: Patients who refuse, cannot tolerate, or do not adhere to CPAP may benefit from oral appliances or surgical interventions. Customized oral appliances should be preferable. Upper airway surgery should be chosen based on patterns of anatomical obstruction. Surgical interventions can also be used as an adjunctive therapy to CPAP (2, B).Recommendation 6: OSA patients with EDS should make lifestyle changes, including correcting poor lifestyle habits and improving sleep hygiene, to improve nocturnal sleep quality and daytime alertness (3, B).Recommendation 7: Pharmacological wake-promoting agents may be considered, after careful clinical evaluation, in OSA patients who meet the following criteria: ① Residual EDS persists despite adequate and adherent conventional OSA therapy (including CPAP, oral appliances, and surgery) with exclusion of other EDS etiologies; ② Patients with EDS who refuse, are intolerant of, or are not compliant with conventional therapy; ③ Patients with EDS that severely impairs quality of life, interferes with work/study performance, or increases the risk of accidents (including those with actual or near-miss accidents) (expert consensus, ungraded).Recommendation 8: For patients with residual EDS despite adequate and adherent conventional OSA therapy, solriamfetol, pitolisant, or modafinil are recommended to improve hypersomnolence (1, A).Recommendation 9: For EDS patients refusing, intolerant or non-adherent to conventional OSA therapy, individualized treatment with solriamfetol or pitolisant is recommended (1, A), with consideration of modafinil (2, B). Regular encouragement to continue conventional OSA therapy should be provided throughout the treatment period.Recommendation 10: Methylphenidate or dextroamphetamine is not currently recommended for OSA-related EDS due to insufficient evidence (no evidence, D).Recommendation 11: Regular monitoring of the efficacy and safety of wake-promoting agents is recommended. The frequency of monitoring should be determined clinically, using subjective EDS scales, and supplemented by objective assessments when available. Strict monitoring for adverse effects is required during treatment, including the risk of drug dependence, addiction, and cardiovascular events. Caution should be exercised when prescribing these agents to patients with cardiovascular risk factors (3, B). 阻塞性睡眠呼吸暂停(OSA)是一种常见的睡眠呼吸疾病。日间嗜睡(EDS)是OSA患者常见临床表现之一,部分OSA患者经常规治疗后仍有残余EDS。EDS严重影响了患者的职业能力和生活质量,增加交通事故风险,加重社会和个人的经济负担。目前国内尚无针对OSA致EDS的诊疗规范。为此,中华医学会呼吸病学分会睡眠呼吸障碍学组专家参考国内外最新研究进展,制订本专家共识。共识针对OSA及其所致EDS的定义、流行病学、临床表现、诊断评估和治疗进行详细阐述,形成11条推荐意见,旨在提供针对OSA致EDS诊断和治疗的规范化的建议,并提高临床医生对OSA致EDS的认识。.
引用
- [Expert consensus on the diagnosis and treatment of excessive daytime sleepiness in obstructive sleep apnea]. Zhonghua Jie He He Hu Xi Za Zhi. 2025. PMID: 40159049. doi:10.3760/cma.j.cn112147-20241118-00681
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。